Drug intelligence / Profile preview

Transcription Factor Program 2

Development stage: Preclinical
Lead developer: Talus Bioscience
Modality: Small Molecules

Overview

Transcription Factor Program 2 is an early-stage drug discovery program developed by Talus Bio, currently in the hit-to-lead phase. The program utilizes Talus Bio's proprietary platform to identify small-molecule modulators of an undisclosed transcription factor for the treatment of autoimmune diseases. The platform focuses on measuring how drugs affect transcription factor activity directly within the cell's nucleus, aiming to target proteins previously considered 'undruggable' due to their lack of traditional binding pockets. By modulating these central regulators of gene expression, the program seeks to develop novel therapies for complex immunological conditions.

Other names: Talus Bio Autoimmune Disease Program

Targets

TF (Transferrin)

Beyond the preview

Go deeper on Transcription Factor Program 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription Factor Program 2.

Explore the full profile